A 72-year-old woman with a 10-year history of osteoporosis has been on alendronate 70 mg weekly for 8 years. She now presents with severe left thigh pain and a pathological fracture of the left femur on imaging. Biochemical markers show suppressed bone turnover (P1NP 25 pg/mL, CTX 0.2 ng/mL; both very low). Serum calcium and phosphate are normal. What is the most likely diagnosis, and what is the recommended next step in management?

Explanation

## Clinical Diagnosis: Atypical Femoral Fracture (AFF) ### Recognition Criteria **Key Point:** This patient meets criteria for AFF, a rare but serious complication of prolonged bisphosphonate therapy: | Feature | Present in This Case | |---------|---------------------| | **Long-term bisphosphonate use** | 8 years of alendronate | | **Suppressed bone turnover markers** | P1NP 25 pg/mL, CTX 0.2 ng/mL (both very low) | | **Subtrochanteric or diaphyseal femoral fracture** | Left femur pathological fracture | | **Minimal or no trauma** | Presented with pain; no trauma history | | **Bilateral risk** | Often bilateral or bilateral-prone | ### Pathophysiology of AFF Bisphosphonates suppress osteoclast activity and bone remodeling. With prolonged use (typically >5 years): 1. Osteoblasts become senescent; bone formation declines 2. Microdamage accumulates without repair (impaired remodeling) 3. Bone becomes brittle despite increased BMD (paradoxical) 4. Stress fractures occur at subtrochanteric/diaphyseal femur (high-stress zones) **High-Yield:** AFF is defined by: - Fracture location: subtrochanteric or diaphyseal femur (NOT femoral neck or intertrochanteric) - Minimal trauma or spontaneous - Often bilateral or prodromal thigh pain - Suppressed bone turnover on markers ## Management Algorithm ```mermaid flowchart TD A["Suspected AFF on long-term BP"]:::outcome --> B{"Confirm diagnosis<br/>imaging + markers"}:::decision B -->|"Confirmed AFF"| C["DISCONTINUE bisphosphonate"]:::urgent C --> D["Ensure vitamin D repletion<br/>25-OH-D > 30 ng/mL"]:::action D --> E["Consider anabolic therapy<br/>Teriparatide 20 mcg SC daily"]:::action E --> F["Orthopedic consultation<br/>Surgical fixation if needed"]:::action F --> G["Monitor for contralateral fracture"]:::action B -->|"Not AFF"| H["Continue BP; investigate<br/>other causes"]:::action ``` ### Recommended Next Steps 1. **Discontinue alendronate immediately** - Continuing bisphosphonate perpetuates suppressed bone turnover and fracture risk - No benefit; high risk of contralateral fracture 2. **Ensure vitamin D repletion** - Target 25-hydroxyvitamin D ≥ 30 ng/mL (preferably 40–50 ng/mL) - Essential for bone healing and osteoblast function recovery 3. **Initiate anabolic therapy (teriparatide)** - Teriparatide 20 mcg subcutaneously daily is the preferred agent - Stimulates osteoblasts and bone formation - Reverses suppressed bone turnover - Reduces fracture risk in AFF patients - Duration: typically 18–24 months 4. **Orthopedic consultation** - Surgical fixation of the femoral fracture (intramedullary nailing or plate fixation) - Screen contralateral femur for prodromal stress fracture **Clinical Pearl:** Teriparatide is the anabolic agent of choice in AFF because it restores bone turnover and promotes healing. Denosumab is contraindicated (further suppresses turnover). Bisphosphonates must be stopped. ## Duration of Bisphosphonate Therapy **Mnemonic: "FLEX" (Fracture Reduction Evaluation of Continuous Alendronate Therapy)** - After 3–5 years of bisphosphonate therapy in stable patients, consider a "drug holiday" (1–2 years off therapy) - Reassess fracture risk; reinitiate if needed - This patient exceeded safe duration; AFF is the consequence ## Why Continued Alendronate Is Harmful Continuing bisphosphonate in AFF: - Perpetuates suppressed osteoblast function - Prevents bone remodeling and microdamage repair - Increases risk of contralateral fracture - Delays healing of the current fracture **Warning:** Do NOT continue alendronate or switch to another bisphosphonate. The class effect (suppressed bone turnover) is the problem.